Key result
A novel torsadogenic risk assessment system using hiPSC-CMs and multi-electrode arrays demonstrated 83% accuracy, 81% sensitivity, and 87% specificity compared to CredibleMeds categorisation.
Why the study?
Does a novel risk assessment system using hiPSC-CMs accurately predict drug-induced torsadogenic risk compared to CredibleMeds?
Population
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
Comparison
Exposure to 60 drugs evaluated using a… vs CredibleMeds® torsadogenic risk categorisation
Design
Preclinical
Authors
Loading...
May aid preclinical torsadogenic screening; leaves open clinical adoption without prospective validation.
Does a novel risk assessment system using hiPSC-CMs accurately predict drug-induced torsadogenic risk compared to CredibleMeds?
Effect estimate: Sensitivity 81%, Specificity 87%, Accuracy 83%
A novel torsadogenic risk assessment system using hiPSC-CMs and MEA demonstrated high accuracy in predicting clinical TdP risk, showing potential to replace the standard hERG assay.
Ando et al. (2016) studied Drug-induced torsadogenic risk. hiPSC-CMs and MEA system vs. CredibleMeds® categorisation was evaluated on Concordance with CredibleMeds® torsadogenic risk categorisation (Sensitivity 81%, Specificity 87%, Accuracy 83%). A novel torsadogenic risk assessment system using hiPSC-CMs and multi-electrode arrays demonstrated 83% accuracy, 81% sensitivity, and 87% specificity compared to CredibleMeds categorisation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: